Literature DB >> 8032081

5-Aminosalicylic acid in pregnancy: clinical report.

G Trallori1, G d'Albasio, G Bardazzi, A G Bonanomi, A Amorosi, P Del Carlo, D Palli, M Galli, F Pacini.   

Abstract

Ulcerative colitis (UC) is a disease condition which typically affects young people; pregnancy is therefore frequent in women with this disease. 5-aminosalicylic acid (5-ASA) is known to be efficacious in maintaining remission of UC, but its safety in pregnancy has not yet been established. In the present study, the safety of 5-ASA was assessed in 16 women with UC (mean age: 31 years, range 25-35) who had a total of 19 pregnancies over the period from 1988 to 1992. All the patients were in clinical remission of UC at the beginning of pregnancy and were receiving a regular maintenance therapy with 5-ASA (ASACOL tablets, 1.2 g/day). During pregnancy, 4 women had a clinical relapse requiring treatment with higher doses of 5-ASA and, in some cases, with steroids. Our observations confirm that the treatment with 5-ASA does not affect the course of pregnancy nor does it damage the fetus, but it can protect from recurrences of UC.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8032081

Source DB:  PubMed          Journal:  Ital J Gastroenterol        ISSN: 0392-0623


  11 in total

Review 1.  IBD and Pregnancy.

Authors:  Audrey H Calderwood; Sunanda V Kane
Journal:  MedGenMed       Date:  2004-10-08

Review 2.  Fertility and pregnancy in the patient with inflammatory bowel disease.

Authors:  U Mahadevan
Journal:  Gut       Date:  2006-08       Impact factor: 23.059

Review 3.  A meta-analysis on the influence of inflammatory bowel disease on pregnancy.

Authors:  J Cornish; E Tan; J Teare; T G Teoh; R Rai; S K Clark; P P Tekkis
Journal:  Gut       Date:  2006-12-21       Impact factor: 23.059

4.  European evidence based consensus on the diagnosis and management of Crohn's disease: special situations.

Authors:  R Caprilli; M A Gassull; J C Escher; G Moser; P Munkholm; A Forbes; D W Hommes; H Lochs; E Angelucci; A Cocco; B Vucelic; H Hildebrand; S Kolacek; L Riis; M Lukas; R de Franchis; M Hamilton; G Jantschek; P Michetti; C O'Morain; M M Anwar; J L Freitas; I A Mouzas; F Baert; R Mitchell; C J Hawkey
Journal:  Gut       Date:  2006-03       Impact factor: 23.059

Review 5.  Indications for 5-aminosalicylate in inflammatory bowel disease: is the body of evidence complete?

Authors:  A A van Bodegraven; Chris J J Mulder
Journal:  World J Gastroenterol       Date:  2006-10-14       Impact factor: 5.742

Review 6.  Pregnancy related issues in inflammatory bowel disease: evidence base and patients' perspective.

Authors:  Christian P Selinger; Rupert Wl Leong; Simon Lal
Journal:  World J Gastroenterol       Date:  2012-06-07       Impact factor: 5.742

Review 7.  Treating inflammatory bowel disease during pregnancy: risks and safety of drug therapy.

Authors:  W Connell; A Miller
Journal:  Drug Saf       Date:  1999-10       Impact factor: 5.606

Review 8.  Comparative tolerability of therapies for ulcerative colitis.

Authors:  Sandro Ardizzone; Gabriele Bianchi Porro
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

9.  Birth outcome in women exposed to 5-aminosalicylic acid during pregnancy: a Danish cohort study.

Authors:  B Nørgård; K Fonager; L Pedersen; B A Jacobsen; H T Sørensen
Journal:  Gut       Date:  2003-02       Impact factor: 23.059

Review 10.  Pregnancy and inflammatory bowel diseases: Current perspectives, risks and patient management.

Authors:  Pegah Hosseini-Carroll; Monica Mutyala; Abhishek Seth; Shaheen Nageeb; Demiana Soliman; Moheb Boktor; Ankur Sheth; Jonathon Chapman; James Morris; Paul Jordan; Kenneth Manas; Felix Becker; Jonathan Steven Alexander
Journal:  World J Gastrointest Pharmacol Ther       Date:  2015-11-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.